NCT06953063

A Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Overweight/Obese Subjects

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study To Evaluate The Efficacy And Safety Of DA-302168S Tablets In Overweight/Obese Subjects

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 240 (estimated)
• Sponsor: Chendu DIAO Pharmaceutical Group CO., LTD. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

It is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the safety and efficacy of DA-302168S tablets in overweight and obese adults.

Detailed description

The goal of the study is to assess how DA-302168S tablets affect the bodyweight when used once daily in obese or overweight adult participants. Qualified participants will be randomly assigned to one of five groups using a computerized system. Following the screening period to confirm eligibility up to 2-weeks, the study will consist of a treatment period will be 16 weeks, followed by an approximate 2-week follow-up.

Conditions

• Overweight and Obesity

Interventions

Type	Name	Description
DRUG	DA-302168S	A small molecule GLP-1R agonist tablet, orally administration, once daily，16weeks.
DRUG	Placebo of DA-302168S	Matching placebo tablet will be provided

Timeline

• Start date: 2025-05-15
• Primary completion: 2025-12-01
• Completion: 2025-12-01
• First posted: 2025-05-01
• Last updated: 2025-06-26

Locations

1 site across 1 country: China